Naringenin-Mediated ATF3 Expression Contributes to Apoptosis in Human Colon Cancer

Hun Min Song, Gwang Hun Park, Hyun Ji Eo and Jin Boo Jeong*

Department of Bioresource Sciences, Andong National University, Andong 760749, Republic of Korea

Abstract

Naringenin (NAR) as one of the flavonoids observed in grapefruit has been reported to exhibit an anti-cancer activity. Activating transcription factor 3 (ATF3) is associated with apoptosis in human colon cancer cells. This study was performed to investigate the molecular mechanism by which NAR stimulates ATF3 expression and apoptosis in human colon cancer cells. NAR reduced the cell viability and induced an apoptosis in human colon cancer cells. ATF3 overexpression increased NAR-mediated cleaved PARP, while ATF3 knockdown attenuated the cleavage of PARP by NAR. NAR increased ATF3 expression in both protein and mRNA level, and increased the luciferase activity of ATF3 promoter in a dose-dependent manner. The responsible region for ATF3 transcriptional activation by NAR is located between -317 and -148 of ATF3 promoter. p38 inhibition blocked NAR-mediated ATF3 expression, its promoter activation and apoptosis. The results suggest that NAR induces apoptosis through p38-dependent ATF3 activation in human colon cancer cells.

Key Words: Naringenin, Activating transcription factor 3, Cancer chemoprevention, Human colon cancer
leads to transcriptional activation of ATF3 which may be associated with induction of apoptosis in human colon cancer cells.

**MATERIALS AND METHODS**

**Reagents**

Naringenin (NAR) was purchased from Sigma Aldrich (St. Louis, MO, USA). Dulbecco’s Modified Eagle medium (DMEM)/F-12 1:1 Modified medium (DMEM/F-12) was purchased from Lonza (Walkersville, MD, USA). Antibodies against ATF3, Poly ADP ribose polymerase (PARP) and β-actin were purchased from Cell Signaling (Beverly, MA, USA). PD98059 (ERK1/2 inhibitor), SB203580 (p38 inhibitor), SP600125 (JNK inhibitor), SB216763 (GSK3β inhibitor) and BAY11-7082 (NF-κB inhibitor) were purchased from Calbiochem (San Diego, CA, USA). ATF3 siRNA was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). ATF3 constructs used in this study were kindly provided from Dr. Seong Ho Lee (University of Maryland, College Park, MD, USA). All chemicals were purchased from Fisher Scientific, unless otherwise specified.

**Cell culture and treatment**

Human colon cancer cell lines such as HCT116, SW480, Lovo and HT-29 cells were purchased from Korean Cell Line Bank (Seoul, Korea) and grown in DMEM/F-12 supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin and 100 μg/ml streptomycin. The cells were maintained at 37°C under a humidified atmosphere of 5% CO₂. NAR was dissolved in dimethyl sulfoxide (DMSO) and treated to cells. DMSO was used as a vehicle and the final DMSO concentration did not exceed 0.1% (v/v).

**Cell viability**

Cell viability was measured using MTT assay system. Briefly, cells (2×10⁴ cells/well) were plated onto 96-well plates and grown overnight. The cells were treated with NAR for 24 h. Then, the cells were incubated with 50 μl of MTT solution (1 mg/ml) for the additional 2 h. The resulting crystals were dissolved in DMSO. The formation of formazan was measured by reading absorbance at a wavelength of 570 nm.

**SDS-PAGE and western blot**

After NAR treatment, cells were washed with 1× phosphate-buffered saline (PBS), and lysed in radiommunoprecipitation assay (RIPA) buffer (Boston Bio Products, Ashland, MA, USA) supplemented with protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO, USA) and phosphatase inhibitor cocktail (Sigma-Aldrich, St. Louis, MO, USA), and centrifuged at 15,000×g for 10 min at 4°C. After determining protein concentration by the bicinchoninic acid (BCA) protein assay (Pierce, Rockford, IL, USA), the proteins were separated on SDS-PAGE and transferred to PVDF membrane (Bio-Rad Laboratories, Inc., Hercules, CA, USA). The membranes were blocked for non-specific binding with 5% non-fat dry milk in Tris-buffered saline containing 0.05% Tween 20 (TBS-T) for 1 h at room temperature and then incubated with specific primary antibodies in 5% non-fat dry milk at 4°C overnight. After three washes with TBS-T, the blots were incubated with horse radish peroxidase (HRP)-conjugated immunoglobulin G (IgG) for 1 h at room temperature and chemiluminescence was detected with ECL Western blotting substrate (Amersham Biosciences, Piscataway, NJ, USA) and visualized in Polaroid film.

**Reverse transcriptase-polymerase chain reaction (RT-PCR)**

After NAR treatment, total RNA was prepared using a RNeasy Mini Kit (Qiagen, Valencia, CA, USA) and 1 μg of total RNA was reverse-transcribed using a Verso cDNA Kit (Thermo Scientific, Pittsburgh, PA, USA) according to the manufacturer’s protocol for cDNA synthesis. PCR was performed using PCR Master Mix Kit (Promega, Madison, WI, USA) with human primers for cyclin D1 and GAPDH as followed: human ATF3: 5'-gtggaggtgtgtaacctgac-3', and reverse 5'-agctgcaatctttcttcgt-3'; human GAPDH: forward 5'-accgagaagcgtggtg-3' and reverse 5'-tcttagacggcagctggt-3'.

**Transient transfections**

Transient transfections were performed using the PolyJet DNA transfection reagent (SignaGen Laboratories, Ijamsville, MD, USA) according to the manufacturers’ instruction. HCT116 and SW480 cells were plated in 12-well plates at a concentration of 2×10⁴ cells/well. After growth overnight, plasmid mix-
tures containing 1 μg of ATF3 promoter linked to luciferase and 0.1 μg of pRL-null vector were transfected for 24 h. The transfected cells were cultured in the absence or presence of NAR for 24. The cells were then harvested in 1×luciferase lysis buffer, and luciferase activity was normalized to the pRL-null luciferase activity using a dual-luciferase assay kit (Promega, Madison, WI, USA).

Transfection of small interference RNA (siRNA)
HCT116 cells were plated in 6-well plates and incubated overnight. HCT116 cells were transfected with control siRNA and ATF3 siRNA for 48 h at a concentration of 100 nM using TransIT-TKO transfection reagent (Mirus, Madison, WI) according to the manufacturer’s instruction. Then the cells were treated with 200 μM of NAR for 24 h.

Expression vector
ATF3 expression vector was provided from Addgene (Cambridge, MA, USA). Transient transfection of the vector was performed using the PolyJet DNA transfection reagent (SignaGen Laboratories, Ijamsville, MD, USA) according to the manufacturers’ instruction.

Statistical analysis
All the data are shown as mean ± SEM (standard error of mean). Statistical analysis was performed with one-way ANOVA followed by Dunnett’s test. Differences with *p<0.05 were considered statistically significant.

RESULTS

Effect of NAR on cell viability and apoptosis in human colon cancer cells
To evaluate whether NAR decreases the viability of human colon cancer cells, HCT116 and SW480 cells were treated with NAR at the different concentrations and cell viability was measured by MTT assay. As a result (Fig. 1A), NAR treatment resulted in the decrease of the cell viability by 28% and 15% at 100 μM, and 47% and 43% at 200 μM in HCT116 and SW480 cells, respectively. In addition, the viability of HT-29 and LoVo cells was decreased by 45% and 49% at 200 μM of NAR, respectively (Fig. 1B). Next, we tested cleaved PARP using Western blot to evaluate whether NAR-mediated decrease of the cell viability results from apoptosis. As shown in Fig. 1C, NAR dose-dependently induced the cleavage of PARP.

Effect of NAR on ATF3 expression in human colon cancer cells
To test whether NAR affects ATF3 expression, we evaluated ATF3 expression in HCT116 and SW480 cells by Western blot. As shown in Fig. 2A, ATF3 expression was increased in NAR (100 and 200 μM)-treated HCT116 and SW480 cells, respectively. In addition, the viability of HT-29 and LoVo cells was decreased by 45% and 49% at 200 μM of NAR, respectively (Fig. 1B). Next, we tested cleaved PARP using Western blot to evaluate whether NAR-mediated decrease of the cell viability results from apoptosis. As shown in Fig. 1C, NAR dose-dependently induced the cleavage of PARP.

Effect of NAR on ATF3 expression in human colon cancer cells
To test whether NAR affects ATF3 expression, we evaluated ATF3 expression in HCT116 and SW480 cells by Western blot. As shown in Fig. 2A, ATF3 expression was increased in NAR (100 and 200 μM)-treated HCT116 and SW480 cells. In time-course experiments (Fig. 2B), ATF3 expression started to increase at 3 h or 1 h after NAR treatment in HCT116 and SW480 cells, respectively. We also evaluated the effect of NAR on ATF3 expression in other colon cancer cells such as LoVo and HT-29. As a result (Fig. 2C), NAR-mediated ATF3 upregulation was observed in both LoVo and HT-29 cells.
Next, HCT116 cells were transfected with ATF3 overexpression vector or ATF3 siRNA to investigate whether NAR-mediated ATF3 increase is associated with transcriptional regulation. As shown in Fig. 2D, 2E, NAR-mediated cleavage of PARP was increased in ATF3 overexpression and decreased in ATF3 knockdown by ATF3 siRNA. These data indicate that ATF3 may be an important molecular target for NAR-mediated apoptosis.

**NAR-mediated ATF3 expression is involved in transcriptional upregulation of ATF3 gene**

To elucidate whether NAR-mediated ATF3 increase is associated with transcriptional regulation, we measured the mRNA level of ATF3. As shown in Fig. 3A, ATF3 mRNA was increased in HCT116 and SW480 cells treated with NAR, which similar to protein expression. In addition, we measured ATF3 promoter activity using ATF3 promoter luciferase constructs (pATF3-1420/+34) to confirm the transcriptional regulation of ATF3 gene by NAR. As shown in Fig. 3B, NAR dose-dependently increased ATF3 promoter activity in HCT116 and SW480 cells.

Next, we performed the promoter assay using different size of ATF3 promoter constructs to elucidate the promoter region responsible for NAR-mediated transcriptional upregulation of ATF3 gene. HCT116 and SW480 cells were transfected with six different size of ATF3 promoter constructs (pATF3-1420/+34, pATF3-718/+34, pATF3-514/+34, pATF3-318/+34, pATF3-147/+34 and pATF3-84/+34) and then treated with NAR or DMSO. As shown in Fig. 3C, NAR-mediated increase of ATF3 transactivation was above 3- or 1.5-fold in HCT116 and SW480 cells transfected with pATF3-318/+34, pATF3-514/+34, pATF3-718/+34 and pATF3-1420/+34, respectively. However, NAR slightly increased ATF3 promoter activity in pATF3-84/+34 and -147/+34 transfected HCT116 and SW480 cells. These data indicate that -317/-148 region of ATF3 promoter may be responsible for NAR-mediated ATF3 promoter activation.

**NAR-mediated ATF3 expression is dependent on p38 activation, but not ERK1/2, JNK, GSK3β and NF-κB**

To elucidate upstream kinases involved in NAR-mediated ATF3 expression, HCT116 cells were pretreated with PD98059 (ERK1/2 inhibitor), SB203580 (p38 inhibitor), SP600125 (JNK inhibitor), BAY 11-7082 (NF-κB inhibitor) or SB216763 (GSK3β inhibitor) for 2 h and then co-treated with NAR for the additional 6 h. As shown in Fig. 4A, p38 inhibition by SB203580 attenuated NAR-mediated ATF3 expression. However, inhibitions of ERK1/2, JNK, NF-κB and GSK3β did not affect ATF3 expression by NAR compared to the cell without the treatment of inhibitors. To confirm that the effect of p38 in NAR-mediated ATF3 expression, ATF3 promoter activity was tested in HCT116 cells transfected with ATF3 promoter constructs (pATF3-1420/+34). As shown in Fig. 4B, p38 inhibition by SB203580 attenuated NAR-mediated ATF3 promoter activation. Next, we evaluated the effect of p38 inhibition on NAR-mediated cleavage of PARP and observed that p38 in-
DISCUSSION

The risk of human cancer can be reduced by the consumption of fruits and vegetables (Pan and Ho, 2008) and approximately 70% of anti-cancer drugs have been developed from natural products (Newman et al., 2002; Yeh et al., 2012). One of the mechanisms for the natural anti-cancer products is through the apoptosis (Pan et al., 2008). According recent reports, NAR expresses ERα and ERβ, which induces apoptosis in colon, breast and uterine cancer cell lines (Totta et al., 2004; Virgili et al., 2004; Bulzoni et al., 2012). However, no other molecular targets involved in NAR-mediated apoptosis have been described. Thus, the elucidation of the additional potential molecular target of NAR for proapoptotic effect may be necessary.

Phytochemicals exert their proapoptotic effect through the regulation of various molecular targets associated with apoptosis. There is a growing body of evidences to suggest that phytochemicals with anti-cancer activity induce apoptosis through upregulating ATF3 expression (Baek et al., 2004; Lee et al., 2005b; Lee et al., 2006; Lee et al., 2013; Kim et al., 2015), which indicates that ATF3 may be one of the important molecular targets for chemoprevention of human colon cancer. In our study, NAR activated ATF3 expression in human colon cancer cell lines such as HCT116, SW480, LoVo and HT-29. In addition, ATF3 overexpression increased NAR-mediated cleavage of PARP and ATF3 knockdown attenuated PARP cleavage by NAR. These findings suggest that ATF3 may be one of the molecular targets for NAR-mediated apoptosis in human colon cancer cells. There are observations indicating that ATF3 inhibits cancer cell proliferation through activating p53 (Yan et al., 2005; Wang et al., 2010) and downregulating cyclin D1 by transcriptional suppression (Lu et al., 2006b). We have reported that NAR downregulates cyclin D1 protein level.

http://dx.doi.org/10.4062/biomolther.2015.109
but not mRNA level resulting in the growth arrest of human colon cancer cells (Song et al., 2015), which indicates that NAR-mediated downregulation of cyclin D1 may be independent on ATF3 activation. Although ATF3 has been regarded as a common molecular target for the proapoptotic effect, specific mechanisms for the apoptotic effect of ATF3 remain unclear. Thus, the further mechanistic study how NAR-mediated ATF3 activation induces apoptosis will be demanded.

ATF3 expression is mainly regulated through its transcription (Hai et al., 1999). Our data shows that NAR activated the expression of ATF3 mRNA and ATF3 promoter activity, which indicates NAR-mediated ATF3 expression may be dependent on transcription. In addition, we determined that NAR-responsive sites for ATF3 transcriptional activity might be between the -317/-148 region in ATF3 promoter.

There is growing evidence that ATF3 expression is regulated by a variety of the upstream kinases (Cai et al., 2000; Baek et al., 2004; Totta et al., 2004). So, we examined whether NAR-mediated ATF3 activation is associated with the activation of ERK1/2, p38, JNK, NF-κB or GSK3β, and found that NAR-mediated ATF3 expression and promoter activity was suppressed in p38 inhibition, but not in the inhibition of other kinases such as ERK1/2, JNK, NF-κB or GSK3β, which indicates that p38 may be an important upstream kinase associated with NAR-mediated ATF3 activation. In the previous study, we have reported that NAR induces p38 activation, which induces cyclin D1 proteasomal degradation in human colon cancer cells (Song et al., 2015). To date, there has been agreement that p38 activation is involved in the induction of ATF3 via various signals such as transcription factors and ROS (Lu et al., 2006a). Among transcription factors, CREB has been reported to plays a role in ATF3 induction (Lu et al., 2006a). In present study, we found that CREB deletion attenuated NAR-mediated ATF3 promoter activation, indicating that CREB may be an important regulator for p38 dependent-ATF3 activation by NAR. In addition, Ahamad et al. has reported that NAR-mediated apoptotic and anti-proliferative activity may result from ROS generation and cell cycle arrest (Ahamad et al., 2014) and ROS have been known to activate p38. Therefore, NAR-induced p38 activation may result from ROS and ROS production may contribute in part to NAR-mediated ATF3 activation.

Taken together, our findings demonstrate that NAR increases the transcriptional activation and increase of ATF3 protein level through p38 activation, and NAR-mediated ATF3 expression contributes least in part to apoptosis in human colon cancer cells. Furthermore, the current study provides information on the apoptotic effect and the potential molecular mechanism of NAR.

ACKNOWLEDGMENTS

This work was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2014R1A1A2053448).

REFERENCES

Ahamad, M. S., Siddiqui, S., Jafari, A., Ahmad, S., Afzal, M. and Arshad M. (2014) Induction of apoptosis and antiproliferative activity of naringenin in human epidermoid carcinoma cell through ROS generation and cell cycle arrest. PLoS One 9, e110003.

Baek, S. J., Kim, J. S., Jackson, F. R., Eling, T. E., McEntee, M. F. and Lee, S. H. (2004) Epicathechin gallate-induced expression of NAG-1 is associated with growth inhibition and apoptosis in colon cancer cells. Carcinogenesis 25, 2425-2432.

Bleiberg, H., Vandenbrouck, A., Deleu, I., Vergauwe, P., Rezaei Kalantari, T., D’Haens, G., Paesmans, M., Peeters, M., Efra, A. and Humbert, Y. (2012) A phase II randomized study of combined intestinal leucovorin sodium and 5-FU versus the levamisole followed by 5-FU both in combination with irinotecan or oxaliplatin in patients with metastatic colorectal cancer. Acta Gastroenterol. Belg. 75, 14-21.

Buizoom, P., Boll, A., Galluzzo, P., Acconcia, F., Ascenzi, P. and Marino, M. (2012) The naringenin-induced proapoptotic effect in breast cancer cell lines holds out against a high bisphenol background. IUBMB Life 64, 690-696.

Cai, Y., Zhang, C., Nawa, T., Aso, T., Tanaka, M., Oshiro, S., Ichijo, H. and Kitajima, S. (2000) Homocysteine-responsive ATF3 gene expression in human vascular endothelial cells: activation of c-Jun NH2-terminal kinase and promoter response element. Blood 96, 2140-2148.

Ekambaram, G., Rajendran, P., Magesh, V. and Saktihsikaren, D. (2008) Naringenin reduces tumor size and weight lost in N-methyl-N-nitro-N-nitrosoguanidine-induced gastric carcinogenesis in rats. Nutr. Res. 28, 106-115.

Esmaeili, M. A. and Alliou, M. (2014) Naringenin attenuates CII induced hepatic inflammation by the activation of Nrf2 mediated pathway in rats. Clin. Exp. Pharmacol. Physiol. 41, 416-422.

Ganapathy, E., Peramaiyan, R., Rajasekaran, D., Venkataraman, M. and Dhanapal, S. (2008) Modulatory effect of naringenin on N-methyl-N-nitro-N-nitrosoguanidine- and saturated sodium chloride-induced gastric carcinogenesis in male Wistar rats. Clin. Exp. Pharmacol. Physiol. 35, 1190-1196.

Garcia-LaFuente, A., Guillamón, E., Villares, A., Rostagno, M. A. and Martinez, J. A. (2009) Flavonoids as anti-inflammatory agents: implications in cancer and cardiovascular disease. Inflamm. Res. 58, 537-552.

Hai, T. and Hartman, M. G. (2001) The molecular biology and nomenclature of the activating transcription factor/cAMP responsive element binding family of transcription factors: activating transcription factor proteins and homeostasis. Gene 273, 1-11.

Hai, T., Wolfgang, C. D., Marsee, D. K., Allen, A. E. and Sivaprasad, U. (1999) ATF3 and stress responses. Gene Expr. 7, 321-335.

Kanno, S., Tomizawa, A., Ohtake, T., Koiwai, K., Ujibe, M. and Ishikawa, M. (2006) Naringenin-induced apoptosis via activation of NF-kappaB and necrosis involving the loss of ATP in human promyelocytic leukemia HL-60 cells. Toxicol. Lett. 166, 131-139.

Kim, K. J., Lee, J., Park, C. H., Jung, K. C., Rhee, H. S. and Yang, C. H. (2005a). Negative regulation of beta-catenin/Tcf signaling by naringenin in AGS gastric cancer cell. Biochem. Biophys. Res. Commun. 335, 771-776.

Lee, S. H., Bahn, J. H., Whitlock, N. C. and Baek, S. J. (2010) Activating transcription factor 2 (ATF2) controls tofifenacin acid-induced ATF3 expression via MAP kinase pathways. Oncogene 29, 5182-5192.

Lee, S. H., Kim, J. S., Yamaguchi, K., Eling, T. E. and Baek, S. J. (2005b) Indole-3-carbinol and 3,3’-diindolylmethane induce expression of NAG-1 in a p53-independent manner. Biochem. Biophys. Res. Commun. 332, 63-69.

Lee, S. H., Min, K. W., Zhang, X. and Baek, S. J. (2013) 3,3’-diindolylmethylene induces activating transcription factor 3 (ATF3) via ATF4 in human colorectal cancer cells. J. Nutr. Biochem. 24, 664-671.

Lee, S. H., Yamaguchi, K., Kim, J. S., Eling, T. E., Safe, S., Park, Y. and Baek, S. J. (2006) Conjugated linoleic acid stimulates an anti-tumorigenic protein NAG-1 in an isomer specific manner. Carcin-
genesis 27, 972-981.
Lu, D., Chen, J. and Hai, T. (2006a) The regulation of ATF3 gene expression by mitogen-activated protein kinases. *Biochem. J.* 401, 559-567.
Lu, D., Wolfgang, C. D. and Hai, T. (2006b) Activating transcription factor 3, a stress-inducible gene, suppresses Ras-stimulated tumorigenesis. *J. Biol. Chem.* 281, 10473-10481
Newman, D. J., Cragg, G. M., Holbeck, S. and Sausville, E. A. (2002) Natural products and derivatives as leads to cell cycle pathway targets in cancer chemotherapy. *Curr. Cancer Drug Targets* 2, 279-308.
Pan, M. H., Ghai, G. and Ho, C.T. (2008) Food bioactives, apoptosis, and cancer. *Mol. Nutr. Food Res.* 52, 43-52.
Pan, M. H. and Ho, C. T. (2008) Chemopreventive effects of natural dietary compounds on cancer development. *Chem. Soc. Rev.* 37, 2558-2574.
Pietta, P. G. (2000) Flavonoids as antioxidants. *J. Nat. Prod.* 63, 1035-1042.
Siegel, R., Ma, J., Zou, Z. and Jemal, A. (2014) Cancer statistics, 2014. *CA Cancer J. Clin.* 64, 9-29.
Song, H. M., Park, G. H., Ko, H. J., Lee, J. W., Kim, M. K., Lee, J. R., Lee, M. H., Koo, J. S. and Jeong, J. B. (2015) Anti-Proliferative Effect of Naringenin through p38-Dependent Downregulation of Cyclin D1 in Human Colorectal Cancer Cells. *Biomol. Ther.* 23, 339-344.
Totta, P., Acconcia, F., Leone, S., Cardillo, I. and Marino, M. (2004) Mechanisms of naringenin-induced apoptotic cascade in cancer cells: involvement of estrogen receptor alpha and beta signalling. *IUBMB Life* 56, 491-499.
Virgili, F., Acconcia, F., Ambra, R., Rinna, A., Totta, P. and Marino, M. (2004) Nutritional flavonoids modulate estrogen receptor alpha signaling. *IUBMB Life* 56, 145-151.
Wang, H., Khor, T. O., Shu, L., Su, Z. Y., Fuentes, F., Lee, J. H. and Kong, A. N. (2012) Plants vs. cancer: a review on natural phytochemicals in preventing and treating cancers and their druggability. *Anticancer Agents Med. Chem.* 12, 1281-1305.
Wang, H., Mo, P., Ren, S. and Yan C. (2010) Activating transcription factor 3 activates p53 by preventing E6-associated protein from binding to E6. *J. Biol. Chem.* 285, 13201-13210.
Yamaguchi, K., Lee, S. H., Kim, J. S., Wimalasena, J., Kitajima, S. and Baek, S. J. (2006) Activating transcription factor 3 and early growth response 1 are the novel targets of LY294002 in a phosphatidylinositol 3-kinase-independent pathway. *Cancer Res.* 66, 2376-2384.
Yan, C., Lu, D., Hai, T. Boyd, D. D. (2005) Activating transcription factor 3, a stress sensor, activates p53 by blocking its ubiquitination. *EMBO J.* 24, 2425-2435.
Yeh, C. C., Yang, J. I., Lee, J. C., Tseng, C. N., Chan, Y. C., Hseu, Y. C., Tang, J. Y., Chuang, L. Y., Huang, H. W., Chang, F. R. and Chang, H. W. (2012) Anti-proliferative effect of methanolic extract of Gracilaria tenuistipitata on oral cancer cells involves apoptosis, DNA damage, and oxidative stress. *BMC Complement. Altern. Med.* 12, 142.
Yen, H. R., Liu, C. J. and Yeh, C. C. (2015) Naringenin suppresses TPA-induced tumor invasion by suppressing multiple signal transduction pathways in human hepatocellular carcinoma cells. *Chem. Biol. Interact.* 235, 1-9.
Yin, T., Sandhu, G., Wolfgang, C. D., Burrier, A., Webb, R. L., Rigel, D. F., Hai, T. and Whelan, J. (1997) Tissue-specific pattern of stress kinase activation in ischemic/reperfused heart and kidney. *J. Biol. Chem.* 272, 19943-19950.
Yoon, H., Kim, T. W., Shin, S. Y., Park, M. J., Yong, Y., Kim, D. W., Islam, T., Lee, Y. H., Jung, K. Y. and Lim, Y. (2013) Design, synthesis and inhibitory activities of naringenin derivatives on human colon cancer cells. *Bioorg. Med. Chem. Lett.* 23, 232-238.